[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100565855":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":29,"centralContacts":33,"locations":42,"responsibleParty":69,"collaborators":71,"id":74,"slug":75,"hasResults":76,"nctId":77,"briefTitle":78,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":76,"sex":81,"minAge":82,"maxAge":83,"enrollmentInfo":84,"targetDuration":10,"studyType":87,"phases":10,"briefSummary":88,"conditions":89,"keywords":10,"overallStatus":95,"whyStopped":10,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":105},{"fullName":5,"class":6},"University Medical Center Groningen","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"TH-combination cohort",null,"L-T4+L-T3 combination according to local protocol.",[13],"Drug: Cytomel (liothyronine)",{"label":15,"type":10,"description":16,"interventionNames":17},"Levothyroxine cohort","L-T4 monotherapy according to local protocol.",[18],"Drug: Euthyrox (levothyroxine)",[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":10},"DRUG","Euthyrox (levothyroxine)","Euthyrox (levothyroxine sodium tablets; L-T4) is a thyromimetic synthetic drug identical to T4. Patients will recieve levothyroxine (euthyrox) in a dose of 2 μg × kg body weight \u002F day.",[15],{"type":21,"name":26,"description":27,"armGroupLabels":28,"otherNames":10},"Cytomel (liothyronine)","Cytomel (liothyronine sodium tablets; L-T3) is a thyromimetic synthetic drug identical to T3.\n\nThe patients in this cohort recieve L-T4+L-T3 combination therapy. The L-T4 dose will be 2 μg × kg body weight \u002F day, equal to the dose in the other interventional arm. L-T3 will be added twice daily from the first day of combination treatment, in dosages gradually decreasing from 25 ug 2\u002Fday to 5 ug 2\u002Fday over a time span of 3 weeks after which L-T3 is stopped.",[9],[30],{"name":31,"affiliation":5,"role":32},"Wouter Zandee, MD\u002FPhD","PRINCIPAL_INVESTIGATOR",[34,39],{"name":35,"role":36,"phone":37,"phoneExt":10,"email":38},"Mirthe Links, BSc","CONTACT","+31 50 3610973","m.h.links@umcg.nl",{"name":31,"role":36,"phone":40,"phoneExt":10,"email":41},"+31 50 3613731","w.t.zandee@umcg.nl",[43,59],{"facility":44,"status":10,"city":45,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"University Medical Center Groningen (UMCG)","Groningen","Provincie Groningen","9700RB","Netherlands","NL",{"type":51,"coordinates":52},"Point",[53,54],6.56667,53.21917,{"lat":54,"lon":53},[57],{"name":58,"role":36,"phone":37,"phoneExt":10,"email":38},"Mirthe Links, Bsc",{"facility":60,"status":10,"city":61,"state":10,"zip":10,"country":48,"countryCode":49,"cosmosGeoPoint":62,"geoPoint":66,"contacts":67},"Radboud University Nijmegen","Nijmegen",{"type":51,"coordinates":63},[64,65],5.85278,51.8425,{"lat":65,"lon":64},[68],{"name":58,"role":36,"phone":37,"phoneExt":10,"email":38},{"type":70,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[72],{"name":73,"class":6},"Radboud University Medical Center","100565855","thyroid-hormone-replacement-after-radio-iodine-value-and-efficacy-100565855",false,"NCT06647602","Thyroid Hormone Replacement After Radio Iodine: Value and Efficacy","THRIVE","Inclusion Criteria:\n\n* Histologically confirmed DTC (papillary thyroid carcinoma, follicular thyroid carcinoma, oncocytic thyroid carcinoma)\n* Classified as high-risk DTC according to the ATA guidelines or, patients for whom the risk of a recurrence is estimated to be higher based on clinical features (assessed by their treating physician).\n* Prepared for RAI-therapy with TH-withdrawal\n* Patients must be fit to adhere to the study protocol\n* Patients must be able to read and understand the Dutch language\n\nExclusion Criteria:\n\n* Pregnancy\n* Patients with comorbidities, such as severe heart failure, (poorly controlled) atrial fibrillation, of which the treating physician decides that L-T3 is unsuitable.\n* Conditions or drugs interfering with thyroid hormone uptake:\n* Patients with a history of atrophic gastritis\n* Patients using proton-pomp inhibitors","ALL","18 Years","75 Years",{"count":85,"type":86},40,"ESTIMATED","OBSERVATIONAL","This study will be a multicentre prospective cohort study on TH-substitution after thyroid hormone withdrawal preceding radioiodine treatment.",[90,91,92,93,94],"Differentiated Thyroid Cancer","Thyroid Cancer","Levothyroxine","Liothyronine","Thyroid Hormones","NOT_YET_RECRUITING","2026-02-05",{"date":98,"type":99},"2026-02-10","ACTUAL",{"date":101,"type":86},"2026-09-01",{"date":103,"type":86},"2028-12-31",{"name":5,"class":6},2]